After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
We received an updated WNV package insert; please note the manufacturer and license number has been ...
As a service to our partners, CTS provides a copy of all licenses and accreditations on our website....
On July 6, 2018 the FDA released an industry guidance document for transitioning from individual to ...
The revised CTS algorithm associated with the Ortho platform is now available for review. Clie...